{"title":"Regional Spirometry by Electrical Impedance Tomography: A Novel Tool for the Assessment of Pulmonary Allograft Function","authors":"Ignacio Fernández Ceballos , Joaquin Ems , Miriam Marcos","doi":"10.1016/j.arbres.2025.07.011","DOIUrl":"10.1016/j.arbres.2025.07.011","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 11","pages":"Pages 714-716"},"PeriodicalIF":9.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.arbres.2025.05.005
Tiina Maarit Andersen , Michelle Chatwin , Manel Luján
{"title":"Current Status and Future of Mechanical Cough Support","authors":"Tiina Maarit Andersen , Michelle Chatwin , Manel Luján","doi":"10.1016/j.arbres.2025.05.005","DOIUrl":"10.1016/j.arbres.2025.05.005","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 11","pages":"Pages 697-700"},"PeriodicalIF":9.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.arbres.2025.04.016
M. Teresa Gómez Hernández , María Suárez Valor , Marcelo F. Jiménez
{"title":"Robotic Tracheobronchoplasty: A Promising Solution for Tracheobronchomalacia Patients","authors":"M. Teresa Gómez Hernández , María Suárez Valor , Marcelo F. Jiménez","doi":"10.1016/j.arbres.2025.04.016","DOIUrl":"10.1016/j.arbres.2025.04.016","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 11","pages":"Pages 712-713"},"PeriodicalIF":9.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.arbres.2025.05.020
Qinglin Zhong , Binglin Lai
{"title":"Type I Cystic Pleuropulmonary Blastoma in a 12-Month Infant","authors":"Qinglin Zhong , Binglin Lai","doi":"10.1016/j.arbres.2025.05.020","DOIUrl":"10.1016/j.arbres.2025.05.020","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 11","pages":"Pages 721-722"},"PeriodicalIF":9.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.arbres.2025.07.017
Dave Singh , Antonio Menéndez Lobo , Andrew Higham , Bernardino Alcázar Navarrete
The goals of COPD treatment are to improve symptoms and decrease future risks such as exacerbations, lung function decline and mortality. Despite receiving maximal inhaled treatment, many COPD patients continue to exacerbate. This highlights the need for novel therapeutic approaches. There is now positive clinical trial data supporting the use of monoclonal antibody treatments in COPD. There remain challenges to define responder populations for each monoclonal antibody class on the basis of clinical characteristics and biomarkers. There are considerable future opportunities, including the targeting of disease activity with monoclonal antibodies at earlier stages in the natural history of COPD in order to slow the rate of disease progression. Using monoclonal antibodies during an exacerbation as a targeted treatment also hold potential. Monoclonal antibody treatments have the potential to change the landscape of COPD management.
{"title":"Biological Therapy in COPD Management: Current Evidence, Challenges and Opportunities","authors":"Dave Singh , Antonio Menéndez Lobo , Andrew Higham , Bernardino Alcázar Navarrete","doi":"10.1016/j.arbres.2025.07.017","DOIUrl":"10.1016/j.arbres.2025.07.017","url":null,"abstract":"<div><div>The goals of COPD treatment are to improve symptoms and decrease future risks such as exacerbations, lung function decline and mortality. Despite receiving maximal inhaled treatment, many COPD patients continue to exacerbate. This highlights the need for novel therapeutic approaches. There is now positive clinical trial data supporting the use of monoclonal antibody treatments in COPD. There remain challenges to define responder populations for each monoclonal antibody class on the basis of clinical characteristics and biomarkers. There are considerable future opportunities, including the targeting of disease activity with monoclonal antibodies at earlier stages in the natural history of COPD in order to slow the rate of disease progression. Using monoclonal antibodies during an exacerbation as a targeted treatment also hold potential. Monoclonal antibody treatments have the potential to change the landscape of COPD management.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 11","pages":"Pages 690-696"},"PeriodicalIF":9.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144940448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.arbres.2025.04.001
Juan Suárez-Antelo , Lucía Ferreiro , José M. Porcel , María Elena Toubes , Óscar Lado-Baleato , Nuria Rodríguez-Núñez , Jorge Ricoy , Adriana Lama , Antonio Golpe , José Manuel Álvarez-Dobaño , Francisco Gude , Luis Valdés
Objective
The therapeutic approach for metastatic malignant pleural effusion depends on the patient's life expectancy. Can survival be accurately estimated in these patients using a risk-prediction model?
Methods
A prospective, single-center study was conducted to examine the prognostic value of pre-established variables (multivariate Cox model). Subsequently, a prognostic score was developed and validated. The inclusion period was 11 years long. Follow-up was conducted until death or for a minimum of 12 months.
Results
The derivation and validation cohorts included 475 and 205 patients, respectively. The prognostic score GASENT (Galicia, Age, Sex, ECOG-PS, Neutrophil/lymphocyte ratio, and Tumor type) was derived from the multivariate analysis of survival.
Categorization of patients in the derivation cohort into low-, moderate-, or high-risk yielded median survival times of 477 days (377–665; n = 159), 108 days (83–156; n = 158), and 35 days (27–47; n = 158), respectively. Survival rates at 1, 3, and 6 months were 92%, 83%, and 72%, respectively, for the low-risk group; 80%, 55%, and 36%, respectively, for the moderate-risk group; and 55%, 23%, and 13%, respectively, for the high-risk group. The analysis of areas under the curve revealed that the GASENT model was superior to the LENT score as a survival predictive model at 1 (0.777 vs. 0.737; p = 0.009), 3 (0.810 vs. 0.778; p = 0.009), and 6 months (0.812 vs. 0.780; p = 0.007).
Conclusions
The GASENT predictive model estimates survival in patients with metastatic malignant effusions with significantly greater accuracy than the scores categorizing patients by risk groups.
{"title":"Predictors of Survival in Metastatic Malignant Pleural Effusions: The GASENT Score","authors":"Juan Suárez-Antelo , Lucía Ferreiro , José M. Porcel , María Elena Toubes , Óscar Lado-Baleato , Nuria Rodríguez-Núñez , Jorge Ricoy , Adriana Lama , Antonio Golpe , José Manuel Álvarez-Dobaño , Francisco Gude , Luis Valdés","doi":"10.1016/j.arbres.2025.04.001","DOIUrl":"10.1016/j.arbres.2025.04.001","url":null,"abstract":"<div><h3>Objective</h3><div>The therapeutic approach for metastatic malignant pleural effusion depends on the patient's life expectancy. Can survival be accurately estimated in these patients using a risk-prediction model?</div></div><div><h3>Methods</h3><div>A prospective, single-center study was conducted to examine the prognostic value of pre-established variables (multivariate Cox model). Subsequently, a prognostic score was developed and validated. The inclusion period was 11 years long. Follow-up was conducted until death or for a minimum of 12 months.</div></div><div><h3>Results</h3><div><span>The derivation and validation cohorts included 475 and 205 patients, respectively. The prognostic score GASENT (Galicia, Age, Sex, ECOG-PS, Neutrophil/lymphocyte ratio, and Tumor type) was derived from the </span>multivariate analysis of survival.</div><div><span>Categorization of patients in the derivation cohort into low-, moderate-, or high-risk yielded median survival times of 477 days (377–665; </span><em>n</em> <!-->=<!--> <!-->159), 108 days (83–156; <em>n</em> <!-->=<!--> <!-->158), and 35 days (27–47; <em>n</em> <!-->=<!--> <span>158), respectively. Survival rates<span> at 1, 3, and 6 months were 92%, 83%, and 72%, respectively, for the low-risk group; 80%, 55%, and 36%, respectively, for the moderate-risk group; and 55%, 23%, and 13%, respectively, for the high-risk group. The analysis of areas under the curve revealed that the GASENT model was superior to the LENT score as a survival predictive model at 1 (0.777 vs. 0.737; </span></span><em>p</em> <!-->=<!--> <!-->0.009), 3 (0.810 vs. 0.778; <em>p</em> <!-->=<!--> <!-->0.009), and 6 months (0.812 vs. 0.780; <em>p</em> <!-->=<!--> <!-->0.007).</div></div><div><h3>Conclusions</h3><div>The GASENT predictive model estimates survival in patients with metastatic malignant effusions with significantly greater accuracy than the scores categorizing patients by risk groups.</div></div>","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 11","pages":"Pages 680-689"},"PeriodicalIF":9.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comparison of the Performance of Algorithms for the Diagnostic Approach to Hypersensitivity Pneumonitis","authors":"Hiram Aguilar-Duran, Ivette Buendia-Roldan, Moises Selman","doi":"10.1016/j.arbres.2025.06.001","DOIUrl":"10.1016/j.arbres.2025.06.001","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 11","pages":"Pages 705-706"},"PeriodicalIF":9.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144339863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-01DOI: 10.1016/j.arbres.2025.05.017
Shuhua Luo, Binglin Lai
{"title":"Lymphoepithelioma-Like Carcinoma Presents as a Bronchial Nodule","authors":"Shuhua Luo, Binglin Lai","doi":"10.1016/j.arbres.2025.05.017","DOIUrl":"10.1016/j.arbres.2025.05.017","url":null,"abstract":"","PeriodicalId":8339,"journal":{"name":"Archivos De Bronconeumologia","volume":"61 11","pages":"Pages 717-718"},"PeriodicalIF":9.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144493792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号